BioSpace News Archive

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, provided preliminary results for the fourth quarter and fiscal year ended January 1, 2021.

Cabozantinib Franchise Preliminary Net Product Revenue of $200 million for the Fourth Quarter 2020, and $741 million for the Full Year 2020

Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that it will participate in the 39th Annual J.P. Morgan Healthcare Conference, which is the largest healthcare investment symposium in the industry.

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, will provide an update on Vision 3x3 and the company’s 2021 key milestones at the 39th Annual J.P. Morgan Healthcare Conference.

Expected total revenue of $464.5-467.5M, including Screening revenue of $249-250M, Precision Oncology revenue of $117-118M, and COVID-19 testing revenue of $98.5-99.5M

The end of 2020 marked a turning point for Canada in our fight against COVID-19. We witnessed Canadian approval of the first two vaccines for COVID-19 - the Pfizer-BioNTech vaccine and the Moderna vaccine, and rollout of initial doses of these vaccines across the country.

Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, reported preliminary, unaudited financial results for the quarter ended December 31, 2020.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced additional results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction who received rexlemestrocel-L or control sham.

Dyne Therapeutics, Inc., a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, announced new preclinical data from its myotonic dystrophy type 1 program demonstrating robust RNA knockdown of toxic human nuclear DMPK, the genetic basis of the disease.

Q4 Product and Service Revenue of $35.7 Million, Including GeoMx Revenue of $12.2 million, Exceeding High End of Guidance Ranges